国际医药卫生导报
國際醫藥衛生導報
국제의약위생도보
INTERNATIONAL MEDICINE & HEALTH GUIDANCE NEWS
2011年
18期
2203-2207
,共5页
张智辉%林少芒%萧剑彬%李强%吴权辉
張智輝%林少芒%蕭劍彬%李彊%吳權輝
장지휘%림소망%소검빈%리강%오권휘
腔内%血管成形%膝下动脉闭塞%重症肢体缺血
腔內%血管成形%膝下動脈閉塞%重癥肢體缺血
강내%혈관성형%슬하동맥폐새%중증지체결혈
Endovascular%angioplasty%Infrapopliteal arterial occlusive%Critical limb ischemia
目的 评价血管腔内术对膝下动脉闭塞疾病的疗效。方法 观察2008年8月-2010年6月间广州医学院第二附属医院血管外科收治的49例(53条患肢)膝下动脉闭塞症患者,分析腔内治疗前后的症状、体征、踝肱指数(ABI)、并发症、随防结果 。结果 53条患肢中,影像学技术成功49条患肢,成功率为92.5%,临床症状明显改善;术后平均随访14月(5~21月),术后1年的通畅率为77.6%,保肢率为91.8%,存活率为95.9%。结论 血管腔内技术能安全、有效治疗膝下动脉闭塞症,提高保肢率,应作为该病血运重建的首选方法。
目的 評價血管腔內術對膝下動脈閉塞疾病的療效。方法 觀察2008年8月-2010年6月間廣州醫學院第二附屬醫院血管外科收治的49例(53條患肢)膝下動脈閉塞癥患者,分析腔內治療前後的癥狀、體徵、踝肱指數(ABI)、併髮癥、隨防結果 。結果 53條患肢中,影像學技術成功49條患肢,成功率為92.5%,臨床癥狀明顯改善;術後平均隨訪14月(5~21月),術後1年的通暢率為77.6%,保肢率為91.8%,存活率為95.9%。結論 血管腔內技術能安全、有效治療膝下動脈閉塞癥,提高保肢率,應作為該病血運重建的首選方法。
목적 평개혈관강내술대슬하동맥폐새질병적료효。방법 관찰2008년8월-2010년6월간엄주의학원제이부속의원혈관외과수치적49례(53조환지)슬하동맥폐새증환자,분석강내치료전후적증상、체정、과굉지수(ABI)、병발증、수방결과 。결과 53조환지중,영상학기술성공49조환지,성공솔위92.5%,림상증상명현개선;술후평균수방14월(5~21월),술후1년적통창솔위77.6%,보지솔위91.8%,존활솔위95.9%。결론 혈관강내기술능안전、유효치료슬하동맥폐새증,제고보지솔,응작위해병혈운중건적수선방법。
Objective To evaluate the clinical effect of endovascular treatment for the infrapopliteal arterial occlusive disease. Methods 49 patients ( 53 limbs ) undergoing endovascular treatment from August 2002 to June 2010 in Department of Vascular Surgery of The Second Affiliated Hospital of Guangzhou Medical College were included. The clinical data and follow-up data were analyzed retrospectively. Results 49 limbs were recanalized with endovascular treatment the technical success rate was 92.5% (49/53). The corresponding symptoms were disappeared or improved obviously. Anklebrachial index(ABI) increased from (0.31 ± 0.19) to (0.83 ± 0.27). The mean follow-up time was 14 months (range 5-21 months). The 12-month accumulated primary patency rate, limbs salvage rate, and survival rate were 77.6%, 91.8%, and 95.9%. Conclusion Endovascular treatment can be performed safely on patients with infrapopliteal arterial occlusive disease. High limb salvage rates can be achieved by Endovascular treatment, and it should be the primary choice for for infrapopliteal arterial occlusive disease in patients with lower extremity ischemia.